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Carbonic anhydrase 9 (CA9) is a protein to be upregulated under exposure to hypoxic conditions. Hypoxic conditions are known to
be associated with resistance to chemotherapy and radiotherapy, and with poor cancer prognosis. We examined CA9 expression in
surgical specimens from oesophageal squamous cell carcinoma (ESCC) patients (n¼127) using immunohistochemistry and real-time
RT–PCR. We also examined CA9 expression and cell proliferation in ESCC cell lines (TE-2, TE-8 and TE-15) and an immortalised
human oesophageal cell line (CHEK-1) using real-time RT–PCR, Western blotting, ELISA and MTT assay. Immunohistochemistry,
high expression of CA9 was found in 63 of the 127 primary tumour specimens and was correlated with poor outcome (P¼0.0003)
and more aggressive/less favourable clinicopathological parameters (tumour size (P¼0.0235), tumour depth (Po0.0001), regional
lymph node metastasis (P¼0.0031), distant lymph node metastasis (P¼0.0077), stage (Po0.0001) and blood vessel invasion
(P¼0.006)). In vitro, CA9 expression in cultured cells and culture medium was also induced by hypoxia (Po0.01). CA9 is correlated
with poor prognosis and malignant phenotype in patients with ESCC, and was upregulated by hypoxia. It is suggested that control of
CA9 expression might improve the effectiveness of chemotherapy and radiotherapy in ESCC.
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Oesophageal cancer is a common malignant neoplasm throughout
the world. Despite recent improvements in surgical techniques,
chemotherapy and radiation treatment, the prognosis for patients
with advanced disease is still unsatisfactory (Collard et al, 2001;
Ando et al, 2003). New approaches to increase the effectiveness of
chemotherapy and radiotherapy need to be developed to improve
the prognosis of oesophageal cancer.
A hypoxia tumour environment is known to be associated with
resistance to chemotherapy and radiotherapy, and with more
malignant tumour phenotypes that show increased invasiveness,
greater metastatic potential and poor survival (Gray et al, 1953;
Brizel et al, 1996; Hockel et al, 1996). Clinical studies have shown a
strong correlation between low pretreatment tumour pO2 and poor
tumour control and overall survival in patients with head and neck
squamous cell carcinoma (Brizel et al, 1999; Nordsmark et al,
2003).
Carbonic anhydrase 9 (CA9), such as hypoxia-inducible factor
1a (HIF-1a), is known to be a marker of hypoxia, but its role in a
hypoxic tumour microenvironment is still unclear (Wykoff et al,
2000). The carbonic anhydrase (CA) family of zinc metalloenzymes
include at least 14 different isoforms in mammals. Some of these
isozymes are cytosolic (CA1, CA2, CA3, CA7, CA13) and others are
membrane-bound (CA4, CA9, CA12 and CA14), whereas CA 5 is
mitochondrial and CA6 is secreted into saliva and milk.
Three cytosolic acatalytic forms are also known (CARP8, CARP10
and CARP11) (Pastorekova et al, 2004). CA is involved in
the reversible hydration–dehydration of carbon dioxide,
CO2þH2O2HCO3
 þH
þ. The CA family plays a variety of roles
in many physiologic processes, including pH regulation and
maintenance of ionic equilibrium (Maren, 1967; Tashian, 1989).
Two of the carbonic anhydrases, CA9 and CA12, are trans-
membrane isozymes that are highly expressed in some tumours,
and may be implicated in acidification of the extracellular milieu
surrounding cancer cells, thus creating a microenvironment
conducive to tumour growth and spread (Pastorek et al, 1994;
Ivanov et al, 1998; Tu ¨reci et al, 1998; Parkkila et al, 2000).
CA9 expression has been associated with poor prognosis in
patients with lung, breast, cervical, brain, and renal cancer (Chia
et al, 2001; Giatromanolaki et al, 2001; Loncaster et al, 2001; Bui
et al, 2003; Brennan et al, 2006; Haapasalo et al, 2006) and
with resistance to chemotherapy in head and neck cancers
(Koukourakis et al, 2001). It has been reported that CA9
expression is an independent prognostic marker in oesophageal
and gastric adenocarcinomas (Driessen et al, 2006), but the
relationship between prognosis and CA9 expression in oesopha-
geal squamous cell carcinoma (ESCC) remains controversial.
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and survival of breast carcinoma cells (Robertson et al, 2004); but
its precise function in normal and cancerous tissues remains
unclear.
The purpose of this study was to investigate CA9 expression in
patients with ESCC, and to confirm changes in the expression level
of CA9 in ESCC cell lines and culture medium under hypoxic
conditions.
MATERIALS AND METHODS
Clinical samples
This study was performed on 127 patients with ESCC who
underwent potentially curative surgery without preoperative
therapy at the Department of General Surgical Science, Gunma
University Graduate School of Medicine, between 1983 and 2004.
Tumour stage was classified according to the sixth edition of the
tumour-node-metastasis classification of the International Union
against Cancer (UICC) (Sobin and Witteking, 2002). All patients
signed informed consent forms in accordance with our institu-
tional guidelines. Information on gender, age, stage of disease, and
histopathologic factors was abstracted from medical records.
Before analysis, the resected specimens were fixed with 10%
formaldehyde, embedded in paraffin blocks, cut into 4-mm thick
sections, and mounted on glass slides. Paraffin-embedded sections
were acquired from all 127 patients (112 males and 15 females).
The median age of these patients was 62 years (range, 40–79
years), and the median survival time was 30.2 months (range,
1–220 months).
Immunohistochemistry
Immunohistochemical staining of the sections for CA9 expression
was performed using the standard streptavidin–biotin peroxidase
complex method, as described earlier (Kato et al, 2002; Fukai et al,
2005). Each 4-mm thick section was deparaffinised, rehydrated and
incubated with fresh 0.3% H2O2 in methanol for 30min at room
temperature to block endogenous peroxidase activity. After
rehydration through a graded series of ethanol concentrations,
the sections were autoclaved in 10mM citrate buffer (pH 6.0) at
1201C for 3min, and then cooled to 301C. After rinsing in 0.1M
phosphate-buffered saline (PBS; pH 7.4), non-specific binding sites
were blocked by incubation with 10% normal goat serum for
30min. The sections were then incubated at 41C overnight with a
rabbit polyclonal antibody (Novus Biologicals Inc., Littleton, USA)
at a dilution of 1:2500 in PBS containing 1% bovine serum
albumin. The sections were then washed in PBS, incubated with
biotinylated anti-rabbit IgG for 30min at room temperature,
and finally incubated in streptavidin–biotin peroxidase complex
solution (Nichirei Co., Tokyo, Japan). The chromogen,
3,30-diaminobenzidine tetrahydrochloride, was applied as a
0.02% solution containing 0.005% H2O2 in 50mM ammonium
acetate–citrate acid buffer (pH 6.0). Finally, the sections were
lightly counterstained with Mayer’s haematoxylin and mounted.
Normal gastric mucosa served as a positive control.
Scoring of CA9 protein expression
CA9 expression was evaluated by calculating an immunostaining
score, which was the product of the intensity score and the staining
rate. Only membranous staining was considered positive. We
evaluated tumours at their surface (n¼121), centre (n¼127) and
invasive front (n¼125). In accordance with the reported criteria
(Chia et al, 2001; Driessen et al, 2006), the intensity score was
based on the estimated staining intensity (0, no staining
(Figure 1A); 1, weak (Figure 1B); 2, moderate (Figure 1C);
3, strong (Figure 1D)), and the staining rate was defined as the
percentage of tumour cells that showed positive staining for CA9
(0–100%). The final immunostaining score (IHC score: 0–300)
was calculated as the product of the staining intensity and the
AB
CD
Figure 1 Photomicrographs (magnification¼ 200) of oesophageal squamous cell carcinoma and gastro-oesophageal junction immunohistochemically
stained for carbonic anhydrase 9 (CA9). (A) The normal gastric mucosa was used as a positive control. The normal oesophageal mucosa was not stained for
CA9; (B) weak staining in the tumour; (C) moderate staining in the tumour; (D) strong staining in the tumour.
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considered to have high CA9 expression if the final score exceeded
the median score (Driessen et al, 2006).
RNA isolation and cDNA synthesis
Total RNA was extracted from fresh-frozen sections and cell lines
using an RNeasy Mini kit (Qiagen, Hilden, Germany) in
accordance with the manufacturer’s instructions. Clinical fresh-
frozen sections were taken from peripheral tumour areas. The
quantity of isolated RNA was measured using an ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington,
Delaware). Template cDNA was synthesised from 13.5mg of total
RNA using an Omniscript Reverse Transcriptase kit (Qiagen),
random primer (hexadeoxyribonucleotide mixture) (TaKaRa,
Shiga, Japan) and ribonuclease inhibitor (Porcine liver) (TaKaRa).
Total RNA was reverse-transcribed with four units of Omniscript
Reverse Transcriptase in a reaction volume of 20ml (60min at
371C, 5min at 931C, and finally on ice). The resulting cDNA
samples were stored at  301C until analysis.
Real-time reverse transcriptase–polymerase chain reaction
Real-time reverse transcriptase (RT)–PCR analyses were per-
formed on an ABI Prism 7000 Sequence detection system (Applied
Biosystems, Foster City, CA, USA). The standard reaction volume
was 20ml and contained 1 SYBR Green PCR Master Mix (ABI),
2.0ml of cDNA template, and both forward and reverse primers at
10mM. The initial PCR denaturation step was performed for 5min
at 951C, followed by 40 cycles of 60s at 951C (melting) and 60s at
601C (annealing/elongation). All reactions were performed in
duplicate. The data were normalised to an internal control gene,
b-actin, to control for the amount of RNA in the preparation.
Oligonucleotide primers for CA9 gene amplification by
RT–PCR
The oligoribonucleotide primers for CA9 were sense primer
50-CCTCAAGAACCCCAGAATAATGC-30; antisense primer 50-CCT
CCATAGCGCCAATGACT-30, and those for b-actin were: sense
primer 50-CTCCTCCTGAGCGCAAGTACTC-30; antisense primer
50-TCCTGCTTGCTGATCCACATC-30. The amplification was
performed for 30 cycles of 30s at 941C, 30s at 621C (551C for
b-actin) and 30s at 721C. Primers for CA9 and b-actin were used
with reference to previously published assays (Furuya et al, 2004;
Simi et al, 2006).
Cell lines
Three human ESCC cell lines and one immortalised human
oesophageal cell line were used: TE-2, TE-8, TE-15 and immorta-
lised human oesophageal cell line (CHEK-1), respectively. TE-2,
TE-8 and TE-15 were kindly provided by Dr T Nishihira, Institute
of Development, Aging and Cancer, Tohoku University School of
Medicine, Sendai, Japan. CHEK-1 cells were kindly provided by
Dr H Matsubara. CHEK-1 was established by transfection of
human papillomavirus type 16 E6/E7 into primary cultures of
human oesophageal keratinocytes (Sashiyama et al, 2002). All
cancer cell lines were derived from ESCC with varying degrees of
differentiation (Nishihira et al, 1993). TE cell lines and CHEK-1
cells were cultured in RPMI-1640 medium (Sigma Chemical Co.,
St Louis, MO, USA) supplemented with 10% fetal bovine serum
and antibiotics (100Uml
 1 penicillin and 100mgml
 1 streptomy-
cin). All cell lines were cultured to 70–80% confluence.
Parallel incubation was performed on aliquots of cells under
normoxic (humidified air with 5% CO2) and hypoxic conditions.
Hypoxic conditions were generated in the APM-30D incubator
(ASTEC Inc., Fukuoka, Japan) with 1% O2,5 %C O 2 and balance N2,
after incubation in normoxic conditions for 24h.
Western blot analysis
Lysates from exponentially growing cell lines were prepared in
buffer (20mM Tris-HCl, pH 7.6, 1mM EDTA, 140mM NaCl, 1%
Nonidet P-40, 1% aprotinin, 1mM phenylmethylsulphonyl fluoride
and 1mM sodium vanadate). The protein concentration was
determined using a BCA Protein Assay Kit (Pierce, Rockford, IL,
USA). Protein (40mg) from each cell line was resuspended in a
sodium dodecyl sulphate (SDS) sample buffer (100mM Tris-HCl,
pH 8.8, 0.01% bromophenol blue, 36% glycerol and 4% SDS)
containing 1mM dithiothreitol, boiled for 10min and applied to a
5–20% gradient Ready-Gel (Bio-Rad, Tokyo, Japan). Proteins
were electrotransferred to a Hybond-enhanced chemilumine-
scence nitrocellulose membrane (Amersham Pharmacia Biotech,
Buckinghamshire, UK). Proteins were immunoblotted using
anti-CA9 (Novus Biologicals Inc.) The bands were detected using
the enhanced chemiluminescence detection system (Amersham
Pharmacia Biotech). For re-blotting, membranes were stripped
according to the manufacturer’s protocol. An anti-b-actin antibody
(Sigma Chemical Co.) served as a control. Horizontal scanning
densitometry was performed using acquisition into Adobe Photo-
shop (Apple Inc., Cupertino, CA, USA) and results were analysed
by Quantity One (Bio-Rad).
ELISA
The CA9 concentration in the cell culture supernatants was
determined by ELISA using a Quantikine
s Human Carbonic
Anhydrase IX/CA9 Immunoassay Kit (R&D Systems, Minneapolis,
MN, USA) in accordance with the manufacturer’s instructions. The
samples were collected from supernatants of cell lines that had
been cultured under normoxic and hypoxic conditions. After
centrifugation at 1500r.p.m., the samples were thawed at 41C
overnight. Then, 50ml of buffered protein base and 100mlo f
sample were added to the wells of a microtitre plate coated with an
anti-CA9 mouse monoclonal antibody and incubated for 2h at
room temperature on a horizontal orbital microplate shaker. The
plate was washed four times, and 200ml of conjugated antibody
solution was then added. After further incubation, the plate was
washed again, 200ml of substrate solution was added, and a third
incubation was carried out for 30min at room temperature, with
protection from light. After the addition of 50ml of stop solution,
colour development was determined immediately at 450nm using
a microtitre plate reader. All samples were assayed three times in a
blinded manner, and the mean was used for data analysis.
In vitro proliferation assay
Cell proliferation was measured in ESCC cells using the MTT
tetrazolium assay. Briefly, ESCC cells (2.5 10
3 per well) were
plated in 96-well plates, 100ml for each well. After initial cell
seeding, the WST-1 assay (Dojin, Tokyo, Japan) was performed,
and 10ml of the cell counting solution was added to each well of the
plates, followed by incubation in a humidified 5% CO2 atmosphere
at 371C for 3h. The formazan was dissolved in 90ml per well 1 N
HCl, and the absorbance of the solution was read at 450nm using a
microtitre plate reader (Becton Dickinson, Franklin Lakes, NJ,
USA). All experiments were performed in triplicate.
Statistical analysis
Statistical analysis was performed using the w
2 test, Fisher’s exact
test and Mann–Whitney U-test. Survival curves were calculated by
the Kaplan–Meier method and analysis was carried out using the
log-rank test. Prognostic factors were examined by univariate and
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Differences at Po0.05 were considered significant. For statistical
analyses, we used Stat View Version 5.0 software (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Clinical samples
Expression of CA9 protein in ESCC Staining for CA9 in the
normal oesophageal squamous epithelium was negative
(Figure 1A), but it was clearly positive in the gastric mucosa used
as a positive control (Figure 1A). In cancer cells, CA9 staining was
seen mainly in the plasma membrane, and at the border of
tumours only the cancerous lesion showed positive staining
(Figure 1B–D). In the tumour centre, 76 (59.8%) of the 127
primary tumour specimens showed CA9 positivity. In the tumour
surface, 39 (32.2%) of the 121 primary tumour specimens showed
CA9 positivity, whereas in the tumour-invasive front, 28 (22.4%) of
125 primary tumour specimens showed CA9 positivity.
Correlations between CA9 expression and clinicopathological
findings For examination of the tumour centre, we divided the
tissue sections into a high group and a low group, on the basis of
their IHC scores (range, 0–250.2; median, 12.8; mean, 46.7). A
median immunostaining score 412.8 was considered to indicate
high CA9 expression. Sixty-three of the 127 patients were classified
in the high CA9 expression group and the other 64 patients were
classified in the low expression group. This classification was in
agreement with earlier reports (Chia et al, 2001; Driessen et al,
2006). The correlation between the clinicopathologic character-
istics of the ESCC patients and tumour centre CA9 expression is
summarised in Table 1. CA9 expression was correlated with
tumour size (P¼0.0235), tumour depth (Po0.0001), regional
lymph node metastasis (P¼0.0031), distant lymph node meta-
stasis (P¼0.0077), stage (Po0.0001) and blood vessel invasion
(P¼0.006). However, there was no significant association between
CA9 expression and other factors, such as age, gender, histological
differentiation, tumour location and lymphatic invasion. We did
scoring for all three parts (tumour surface, tumour centre and
invasive front) using the method that we described in the paper.
Table 1 Correlations between clinicopathological characteristics and CA9 expression
CA9 (n¼64) CA9 (n¼63)
Parameters Total (n¼127) Low High P-value
Age (mean±s.d.,
a years) 61.9±8.7 61.8±8.3 62.0±9.1 0.87
b
Gender 0.0503
c
Male 112 60 52
Female 15 4 11
Tumour size (mean±s.d.,
a cm
2) 17.1±15.6 13.7±17 20.2±13 0.0235
b
Differentiation 0.5429
c
Well 29 12 17
Moderate 66 35 31
Poorly 32 17 15
TNM clinical classification pT (tumour depth) o0.0001
d
T1 54 46 8
T2 14 5 9
T3 51 13 38
T4 8 0 8
pN (regional lymph node metastasis) 0.0031
c
N0 57 37 20
N1 70 27 43
pM (distant metastasis) 0.0077
c
M0 106 59 47
M1 21 5 16
pStage o0.0001
d
I3 9 3 4 5
II 36 16 20
III 31 9 22
IV 21 5 16
Location 0.4777
c
Upper 31 13 18
Middle 79 48 36
Lower 17 8 9
Lymphatic invasion 0.0643
c
Negative 40 25 15
Positive 87 39 48
Blood vessel invasion 0.006
c
Negative 64 40 24
Positive 63 24 39
as.d.
bStudent’s t-test.
cw
2 test.
dFisher’s exact test.
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pathological parameters and CA9 staining assessed at the tumour
surface or invasive front.
Prognostic significance of CA9 expression The survival rate of
patients with tumours showing low CA9 expression was signifi-
cantly higher than that of patients with tumours showing high CA9
expression (P¼0.0003; Figure 2). The 5-year survival rate for
patients with low CA9 expression was significantly higher than that
of patients with high CA9 expression (66.5 vs 33.3%). In univariate
Cox proportional hazards analysis, primary tumour (T), regional
lymph node metastasis (N), distant metastasis (M), TNM stage (S)
and CA9 expression were the strongest prognostic factors for
cancer-specific survival. However, tumour CA9 expression in
ESCC patients was not identified as an independent prognostic
factor in multivariate survival analysis using Cox proportional
hazards analysis (Table 2).
CA9 mRNA expression determined by real-time RT–PCR To
confirm CA9 mRNA expression, we analysed 35 clinical samples,
including normal and tumour tissue. All samples quantified values
used to calculate CA9/b-actin expression ratios. In this group of
paired samples, CA9 mRNA expression levels were significantly
higher in tumour tissues (0.022±0.038) (mean±s.d.) than in
normal tissues (0.009±0.016). This resulted in a significant
difference in the mRNA expression level between tumour and
normal tissues (P¼0.0019; Figure 3).
Cell lines
Expression of CA9 mRNA cell lines during normoxia and
hypoxia We initially investigated the mechanism of CA9 regula-
tion in ESCC during hypoxia by examining mRNA expression. We
cultured the cell lines TE-2, TE-8 and TE-15 for 24h under hypoxic
conditions (1% O2). We then compared CA9 mRNA levels between
hypoxic and normoxic conditions using RT–PCR. In all three cell
lines, expression of CA9 mRNA was upregulated under hypoxic
conditions (Figure 4).
Expression of CA9 in ESCC cell line TE-2 under hypoxic
conditions We compared the temporal expression of CA9 mRNA
in the ESCC cell line TE-2 and in the CHEK-1 under hypoxic
conditions. In TE-2 cells, the ratio between CA9 mRNA expression
during hypoxia relative to normoxia increased markedly with time
(Figure 5A). We used Western blotting to examine the expression
of CA9 protein in the TE-2 cells. At the protein level, expression of
CA9 increased with time under hypoxic but not normoxic
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Figure 2 Association of carbonic anhydrase 9 (CA9) tumour expression
with outcome in 127 patients with oesophageal squamous cell carcinoma.
Cancer-specific survival rates at 5 years after surgery were 66.5% for the
CA9 low expression group and 33.3% for the CA9 high expression group.
Kaplan–Meier curve is shown (P¼0.0003, log-rank test).
Table 2 Prognostic significance of CA9 expression and clinicopathologic parameters
Risk factor Reference factor P-value Hazard ratio 95% CI
a
Univariate
Age 624 vs 62o 0.1947 1.437 0.831–2.484
Histological grade G1,G2 vs G3 0.0590 1.749 0.979–3.125
Primary tumour (T) T1,T2 vs T3,T4 o0.0001 7.012 3.692–13.32
Regional lymph node metastasis (N) Negative vs positive o0.0001 7.697 3.462–17.11
Distant metastasis (M) Negative vs positive o0.0001 3.990 2.147–7.416
TNM stage (S)
b S1,S2 vs S3,S4 o0.0001 8.302 4.409–15.63
CA9 expression Low vs high 0.0006 2.782 1.556–4.973
Multivariate
Primary tumor (T) T1,T2 vs T3,T4 0.0001 4.240 2.030–8.856
Regional lymph node metastasis (N) Negative vs positive 0.0003 4.620 2.010–10.62
CA9 expression Low vs high 0.7859 1.093 0.575–2.078
Cox proportional hazards analysis.
aConfidence interval.
bUICC (International Union Against Center) TNM classification.
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Figure 3 Expression of CA9 mRNA in non-cancerous and cancer tissues
from patients with oesophageal squamous cell carcinoma patients (n¼35)
assessed by real-time RT–PCR. Horizontal lines indicate mean values for
each group. (N, non-cancerous tissue; T, cancer tissue) (P¼0.0019,
Mann–Whitney U-test).
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protein did not increase under either normoxic or hypoxic
conditions (data not shown). This confirmed that CA9 protein
was induced by hypoxia. We also measured the expression of CA9
protein in the cell culture medium using ELISA and, interestingly,
we found that CA9, which is a membrane protein, was present in
the cell culture medium. The level of CA9 in the culture medium
under hypoxic conditions was increased significantly when
compared with that under normoxic conditions (Po0.01;
Figure 5C).
Proliferation of ESCC cell lines under hypoxic conditions We
measured cell proliferation in two ESCC cell lines (TE-2 and
TE-15), under hypoxic conditions, using the MTT assay. Each
sample was measured three times. Both TE-2 and TE-15 cells
proliferated significantly more under hypoxic than under nor-
moxic conditions (Po0.01; Figure 6). In addition, the tendency for
cell proliferation resembled a change of CA9 expression shown by
ELISA.
DISCUSSION
We investigated the expression of CA9 in ESCC at both the protein
and mRNA levels, and found that CA9 protein was expressed in
tissue samples from 76 of 127 (59.8%) tumours. CA9, similar to
HIF-1 (Pantuck et al, 2003), is a member of the hypoxia-induced
pathway and is thought to be expressed specifically around the
tumour centre, where hypoxic conditions prevail. We therefore
performed CA9 scoring for three parts (tumour surface, centre and
invasive front), but only the scores from the tumour centre were
included in the statistical analyses. Our results reflected those
obtained in studies of other solid tumours. Expression of CA9 has
been reported in 48% of breast cancers (Chia et al, 2001), 79% of
cervical cancers (Loncaster et al, 2001) and 81% of lung cancers
(Swinson et al, 2003). However, in oesophageal cancer, many
indicators of poor prognosis, such as Ki-67 and PCNA, which are
cell proliferation markers, are expressed at the invasive front of the
tumour. In this study, we found no significant correlation between
CA9 expression at the tumour surface and invasive front and
clinicopathological findings and prognosis (data not shown). In
terms of IHC score, CA9 expression was significantly associated
with tumour staging and poor prognosis. In other solid tumours,
CA9 protein has been reported to be an independent factor related
to poor prognosis (Chia et al, 2001; Loncaster et al, 2001; Brennan
et al, 2006; Haapasalo et al, 2006; Lee et al, 2007). Driessen et al
reported that CA9 expression was an independent prognostic
marker in oesophageal cancers, especially adenocarcinomas and
gastric cancer (Driessen et al, 2006), whereas in another study of
oesophageal tumours, the degree of CA9 staining did not correlate
RT–PCR (30 cycles)
CA9
-actin
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N HN H N H
TE-15
Figure 4 Expression of CA9 mRNA assessed by RT–PCR in
oesophageal squamous cell lines under normoxic and hypoxic conditions.
Cell lines were cultured for 24 hours. Hypoxic conditions were generated
with 1% O2 (N, normoxic; H, hypoxic).
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Figure 5 In vitro assay for CA9 induced by hypoxia in an oesophageal squamous cell carcinoma line (TE-2) and in culture medium. (A) Comparison of
CA9 mRNA expression in TE-2 cells and in the immortalised human oesophageal cell line (CHEK-1). CA9 expression was measured by real-time RT–PCR;
(B) Expression of CA9 protein in TE-2 cells was measured by western blotting. Expression of CA9 protein was higher under hypoxic conditions;
(C) Expression of CA9 protein in culture medium was significantly induced under hypoxic conditions (Po0.01). All examinations were done in triplicate.
(N, normoxic; H, hypoxic).
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1997). In our present study of ESCC, expression of CA9 protein
was not independently related to poor prognosis. CA9 is a marker
of hypoxia, and its expression is significantly correlated with
tumour size. As a tumour grows in size, its centre gradually
becomes starved of oxygen, and high expression of CA9 might
therefore indicate that a tumour has a greater propensity for
enlargement.
We studied the expression of CA9 mRNA in both normal and
tumour tissues from 35 patients, using real-time RT–PCR. At the
mRNA level, there was no significant correlation between CA9
expression and clinicopathological findings and prognosis (data
not shown). In non-small-cell lung cancer, increased expression of
CA9 mRNA in cancer tissues was significantly correlated with
increased expression of the protein (Simi et al, 2006). However, in
our study, we found no such correlation, perhaps because tissue
samples were collected from the peripheral tumour areas, rather
from the centre.
We confirmed in vitro that CA9 mRNA was expressed under
hypoxic conditions in three ESCC cell lines, TE-2, TE-8 and TE-15,
suggesting that upregulation of CA9 was controlled at the mRNA
level. We also confirmed that CA9 was expressed at the protein
level in these three ESCC cell lines under hypoxic conditions.
Similar results have been reported for meningiomas (Yoo et al,
2007) and for several cell lines (Swinson et al, 2003; Robertson
et al, 2004; Le et al, 2005). Comparison of the ESCC cell line TE-2
with an immortalised oesophageal cell line, CHEK-1, showed that
expression of CA9 mRNA was induced in both under hypoxic
conditions; however, the degree of CA9 expression differed greatly
between the protein and the mRNA. This result suggests that CA9
might be induced in cells with higher malignant potential.
In this study, we also confirmed the presence of CA9 protein in
the cell culture medium, a finding that has not been reported
earlier. In ESCC cell lines, the level of CA9 in the culture medium
was significantly increased under hypoxic conditions. CA9 is a
membrane protein, and so it was very interesting to see that CA9
was present within the culture medium. It is unclear whether CA9
was secreted by the cancer cells or whether it was released from
damaged cancer cells. In addition, we confirmed that oesophageal
cancer cells under hypoxic conditions proliferated faster than cells
under normoxic conditions, suggesting that CA9 has a role other
than pH regulation alone. Robertson et al (2004) described that
cells treated with CA9 interfering showed delayed growth under
hypoxic conditions. In our study, cell proliferation and CA9
expression were induced under hypoxic conditions, suggesting
that CA9 expression was correlated with cell proliferation.
In conclusion, our study has shown that hypoxia induces CA9
expression in ESCC and that this is related to poor prognosis.
It has already been reported that (i) hypoxic conditions associated
with tumours are related to resistance to chemotherapy
and radiotherapy (Gray et al, 1953; Brizel et al, 1996; Hockel
et al, 1996); (ii) low extracellular pH is a typical feature of the
tumour microenvironment, which has an impact on cancer
development (Svastova ´ et al, 2004); and (iii) CA9 contributes to
tumour growth and survival (Robertson et al, 2004). In addition,
some ESCCs are relatively sensitive to chemotherapy and radio-
therapy. Therefore, to improve the results of cancer therapy, it is
important to control CA9, which is induced under hypoxic
conditions and acidifies the tumour milieu. It is suggested that
inhibition of CA9 may improve the effectiveness of chemotherapy
and radiotherapy.
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